Life Sciences
Navigate forward to interact with the calendar and select a date. Press the question mark key to get the keyboard shortcuts for changing dates.
Navigate backward to interact with the calendar and select a date. Press the question mark key to get the keyboard shortcuts for changing dates.
Innovation is essential to promoting human health, agricultural productivity, and ecological sustainability. ITIF’s Center for Life Sciences Innovation conducts research supporting advances in human biotechnology; pharmaceuticals; and health care policy outside the realm of IT.
Featured
Evidence to Inform Biopharmaceutical Policy: A Call for Research on the Impact of Public Policies on Investment in Drug Development
The scope and magnitude of the trade-off between immediate savings from lower drug prices and future health benefits from clinical development remain poorly understood and quantified. To support rigorous evaluations and inform evidence-based policymaking, it is crucial to invest in this area through research grants and improved access to federal and private data.
Evidence-Based Biopharmaceutical Policymaking: Symposium Report
There is a need for more rigorous evidence and more recent, high-quality data to inform biopharmaceutical policymaking by shedding light on the relationship between pharmaceutical firms’ expectations of financial returns from new drugs and their ability to invest in further R&D to discover future generations of drugs.
How Skeptics Misconstrue the Link Between Drug Prices and Innovation
A recent article in the British Medical Journal contends “high drug prices” are neither necessary nor justified to sustain biopharmaceutical innovation. But it misrepresents and misinterprets the facts, highlighting how faulty the rationale is for drug price controls.
The Hidden Toll of Drug Price Controls: Fewer New Treatments and Higher Medical Costs for the World
When nations implement pharmaceutical price controls, they reduce pharmaceutical revenues, which then reduces investments in further R&D, limiting future generations’ access to new novel treatments needed to fight diseases such as cancer, Alzheimer’s, heart disease, and diabetes.
More Publications and Events
December 10, 2024|Events
Innovate4Health: How IP and Innovation Are Solving Global Health Challenges
Please join ITIF, the Geneva Network, and the University of Akron School of Law for an event releasing a new report profiling 24 pioneering case studies from five regions—Latin America, Africa, South Asia, Southeast Asia, and Middle East and North Africa—where IP rights have enabled innovators to create impactful health solutions, particularly in the developing world.
November 18, 2024|Press Releases
AI Can Transform Drug Development, New ITIF Report Finds
AI has the potential to cut drug development times nearly in half, and ITIF’s new report highlights the transformative impact and policy needs to make it happen.
November 15, 2024|Reports & Briefings
Harnessing AI to Accelerate Innovation in the Biopharmaceutical Industry
AI has the potential to transform drug development by enhancing productivity across the entire development pipeline, boosting biopharmaceutical innovation, accelerating the delivery of new therapies, and fostering competition to help improve public health outcomes.
November 15, 2024|Events
2024 Global Trade and Innovation Policy Alliance Summit
This event will feature keynotes and panels with speakers from GTIPA member organizations; experts on trade, globalization, innovation, and IP policy issues; and leaders from India’s business, academic, and policymaking communities.
November 13, 2024|Testimonies & Filings
Comments to the UK’s Department for Business and Trade Regarding the Modern Industrial Strategy Green Paper
The UK government needs to make a choice: competitiveness and growth or heavy-handed regulation in the service of social policy. It can have one but not both.
October 4, 2024|Blogs
Draghi Wants to Have His Drug Cake and Eat It Too
Mario Draghi's 2024 report addresses the EU's biopharmaceutical decline, citing challenges like underfunded research, fragmented pricing, and competition from the U.S. and China. It recommends reforms but underplays the impact of EU drug price controls on innovation.
October 3, 2024|Publications
Guidelines for Grant Proposals on Evidence-Based Biopharma Policy
The Information Technology and Innovation Foundation will offer grants for new research that helps to inform the relationship between the expectation of a financial reward for an approved new drug or new indication in the United States and the (1) investment in research and development for new and existing drugs, and/or (2) the approval of new drugs and new indications.
August 28, 2024|Blogs
Alzheimer’s Disease Next Game Changer: TauRx Pharmaceutical’s Novel Tau Aggregation Inhibitor
TauRx is revolutionizing Alzheimer's treatment with a novel drug that targets toxic brain proteins, offering fresh hope in the fight against this devastating disease.
August 26, 2024|Blogs
Fact of the Week: The Price of Drugs Has Increased 40 Percent Less Than the Average US Product
Despite popular rhetoric around the supposedly exorbitant prices of prescription drugs, the price of pharmaceutical products has increased far slower than the rate of inflation.
August 16, 2024|Blogs
Innovative Cure For All: How CurASeal’s Plant-Based Technology Advances Bleeding Control and Wound Healing
InCurA is revolutionizing MENA's medical landscape with AI-optimized, locally produced hemostatic solutions like CurASeal, bridging the gap between innovation and accessibility while reducing reliance on global imports.
